Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients

• What are the most crucial technical challenges in translating LNP formulations from preclinic to human studies?
• As the field moves from early clinical programs to commercialization, what are the key challenges in translating LNP formulations from small-scale development into robust, large-scale manufacturing processes?
• How to optimize the dosing strategies for LNPs to ensure safe and effective therapeutics?

Speakers:

Annette Bak

Executive Director

AstraZeneca

Ching Kim Tye

Head of DP Platform and Early Clinical Development

Sanofi

Luis Brito

Vice President - Delivery Platform

Beam Therapeutics

Michael Smith

Senior Scientist - Drug Product Development

Moderna

Wolfgang Hofmann

ceo

Leon-Nanodrugs GmbH